What is the challenge?
There are over 50 million people worldwide living with dementia and by 2030 this number is expected to reach 82 million.
The ageing brain becomes vulnerable to decline and keeping independency in daily life can become a challenge for the elderly. People with Mild Cognitive Impairment (MCI), an intermediate condition between normal brain ageing and dementia, may develop dementia in the future.
There is an urgent need for early risk assessment and intervention. Current practices with time-consuming patient investigations focus on late symptoms management due to a lack of diagnostic tools. This causes numerous implications in terms of familial, medical and care costs.
With AI-Mind we aim to reduce the disease’s burden by developing novel, AI-based tools to support healthcare professionals in their diagnosis and offering timely interventions to patients.
At the heart of AI-Mind is our research study, that
Takes place in Norway, Finland, Italy and Spain and will involve 1,000 participants.
Helps to develop and validate artificial intelligence (AI) based tools to predict who is likely to develop dementia.
Visit our local study pages to learn more
Latest news below
New publication from AI-Mind on Framework for Evaluating AI-Based Health Technologies
New publication from AI-Mind on Framework for Evaluating AI-Based Health Technologies The AI-Mind project is
Positive EMA decision on lecanemab highlights importance of AI-Mind’s work
Positive European Medicines Agency decision on lecanemab highlights importance of AI-Mind’s work On 14 November
AI-Mind
-
External advisors from ethics, neuroscience, AI, modelling and economics
-
Advocacy groups for patients and physicians